Top Markets
#1 Ontology Gas Ontology Gas +26.68%
#2 Verus Coin Verus Coin +22.51%
#3 EXOD EXOD +22.08%
#4 ETHGas ETHGas +17.69%
#5 Status Status +17.53%
#6 Geodnet Geodnet +14.38%
#7 Derive Derive +12.51%
#8 Curve DAO Curve DAO +11.86%
#9 The Black Bull The Black Bull +10.06%
#10 Anvil Anvil +9.81%
Coin of the day
Ontology Gas Ontology Gas
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Kedudukan dalam Saham #25519
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Harga Saham
$9.81
Disegerakkan terakhir: 2025-03-18
Modal Pasaran
$48.68M
Perubahan (1 hari)
1.55%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan AlloVir, Inc. (ALVR)

Kategori

Healthcare
Pendapatan untuk AlloVir, Inc. (ALVR)
Pendapatan pada Jun 2026 TTM: $-54.46M
Menurut laporan kewangan terkini AlloVir, Inc., pendapatan semasa syarikat ialah $-54.46M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-190.54M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-168.98M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi AlloVir, Inc. dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-54.46M -7.33%
2024 $-58.77M -69.16%
2023 $-190.54M 12.76%
2022 $-168.98M -1.16%
2021 $-170.96M 144.98%
2020 $-69.78M 192.73%
2019 $-23.84M 881.03%
2018 $-2.43M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -9,786.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -3,681.87%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -3,064.22%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 5,568.48%
US